Sector
PharmaceuticalsOpen
₹8,051Prev. Close
₹8,129.9Turnover(Lac.)
₹1,329.93Day's High
₹8,371.25Day's Low
₹8,05152 Week's High
₹8,65052 Week's Low
₹3,133Book Value
₹994.26Face Value
₹10Mkt Cap (₹ Cr.)
10,510.63P/E
34.76EPS
233.75Divi. Yield
0.1711 May 2023
12:00 AM
AGM
Announcement Date: 11 May, 2023
23 Apr 2024
12:00 AM
Board Meeting
Agenda : Audited Result
10 May 2024
12:00 AM
Dividend
Dividend Amount: 14
10 May 2024
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 12.9 | 12.9 | 12.9 | 12.9 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,263.64 | 975.46 | 822.67 | 768.98 |
Net Worth | 1,276.54 | 988.36 | 835.57 | 781.88 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
|---|---|---|---|---|
Revenue | 951.07 | 936.91 | 762.71 | 666.82 |
yoy growth (%) | 1.51 | 22.83 | 14.37 | 26.43 |
Raw materials | -422.13 | -438.41 | -380.19 | -366.24 |
As % of sales | 44.38 | 46.79 | 49.84 | 54.92 |
Employee costs | -175.75 | -144.02 | -118.48 | -104.47 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
|---|---|---|---|---|
Profit before tax | 81.73 | 104.96 | 52.49 | 19.83 |
Depreciation | -49.03 | -39.67 | -31.27 | -25.86 |
Tax paid | -18.2 | -24.66 | -36.61 | -3.69 |
Working capital | 83.75 | -74.79 | 43.14 | 0.41 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 1.51 | 22.83 | 14.37 | 26.43 |
Op profit growth | -2.9 | 44.33 | 75.33 | 15.66 |
EBIT growth | -22.48 | 65.87 | 108.65 | 9.35 |
Net profit growth | -20.87 | 405.63 | -1.63 | 36.71 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 1,558.58 | 1,191.2 | 951.08 | 936.91 | 762.71 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,558.58 | 1,191.2 | 951.08 | 936.91 | 762.71 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 12.54 | 9.75 | 2.08 | 16.1 | 3.89 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman
D R Rao
Non Executive Director
Christopher M Cimarusti
Vice Chairman & CEO
D Sucheth Rao
Vice Chairman & M.D.
D Saharsh Rao
Company Sec. & Compli. Officer
Sarada Bhamidipati
Independent Director
Nirmala Murthy
Independent Director
Homi Rustam Khusrokhan
Independent Director
Prasad R Menon
Independent Director
Sugata Sircar
Independent Director
Pallavi Joshi Bakhru
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Neuland Laboratories Ltd
Summary
Set up in 1984 as a private limited company to manufacture bulk drugs, Neuland Laboratories (NLL) is promoted by Davuluri Sucheth Rao. Neuland Drugs & Pharmaceuticals Pvt Ltd, a company set up by the same promoters to manufacture bulk drugs was merged with NLL with effect from Apr.92. NLL manufactures bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin. The Company came out with its initial public offering in Apr.94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix. The cost of the project as estimated by ICICI was Rs 15.7 cr.NLLs products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate.During the year 1999-2000, the company introduced Itraconazole, an anti-fungal drug and Ipratropium Bromide, an anti-asthmatic drug and the R & D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form.Mirtrazapine, an anti-depressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI.The Co
Read More
What is the Neuland Laboratories Ltd share price today?
The Neuland Laboratories Ltd shares price on N/A is Rs.₹8180.2 today.
What is the Market Cap of Neuland Laboratories Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Neuland Laboratories Ltd is ₹10495.11 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Neuland Laboratories Ltd?
The PE and PB ratios of Neuland Laboratories Ltd is 34.76 and 8.17 as of 22 Jul ‘24
What is the 52 Week High and Low of Neuland Laboratories Ltd?
The 52-week high/low is the highest and lowest price at which a Neuland Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Neuland Laboratories Ltd is ₹3100.05 and ₹8649 as of 22 Jul ‘24
What is the CAGR of Neuland Laboratories Ltd?
Neuland Laboratories Ltd's CAGR for 5 Years at 74.56%, 3 Years at 55.35%, 1 Year at 159.37%, 6 Month at 37.19%, 3 Month at 10.26% and 1 Month at 25.15%.
What is the shareholding pattern of Neuland Laboratories Ltd?
The shareholding pattern of Neuland Laboratories Ltd is as follows:
Promoters - 32.72 %
Institutions - 32.52 %
Public - 34.76 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
